NeuroSearch successfully completes End of Phase II meeting with the FDA for tesofensine, a treatment for obesity
June 08, 2009 02:55 ET
|
NTG Nordic Transport Group A/S
- FDA endorses the overall Phase III plan for tesofensine in obesity, including
the filing of an NDA based on 12 months safety and efficacy data
- NeuroSearch will now finalise Phase III...
Presentation to be held at Aker Solutions ASA's Extraordinary General Meeting
June 08, 2009 02:54 ET
|
Akastor ASA
Please find attached the presentation to be held at Aker Solutions ASA's Extraordinary General Meeting today, 8 June 2009 at 09:00 CET in Oslo.
ENDS
For further...
STOCK EXCHANGE CALENDAR WEEK 24/2009
June 08, 2009 02:52 ET
|
Nasdaq Tallinn
* * * * * * * * * * * * *
REDEMPTION AND INTEREST EX-DATE
Wed 10.06 - SEB Pank AS
* * * * * * * * * * * * *
NASDAQ OMX Tallinn
Market Services
+372 640...
er den 8. juni 2009 opgjort til 76,41 kr.
June 08, 2009 02:48 ET
|
Alm. Brand Formue A/S
Indre værdi for Alm. Brand Formue A/S.
...
Prospektmeddelelse - Ny afdeling Emerging Markets Aktier
June 08, 2009 02:46 ET
|
Investeringsforeningen Gudme Raaschou
Hermed fremsendes prospektmeddelelse vedrørende ny afdeling Emerging Markets
Aktier i Investeringsforeningen Gudme Raaschou.
...
CHANGES IN SUBSTANTIAL SHAREHOLDINGS
June 08, 2009 02:40 ET
|
Nasdaq Tallinn
As of 08.06.2009 the following significant changes have taken place in the
ownership structure of the companies listed on the NASDAQ OMX Tallinn,
compared with the standings disclosed...
Substansvärde 2009-06-05: 55 SEK/aktie
June 08, 2009 02:37 ET
|
Svolder AB
Substansvärde 2009-06-05: 55 SEK/aktie
Svolders substansvärde var oförändrat med 55 SEK/aktie föregående vecka.
Hittills under kalenderåret 2009 har Svolders substansvärde ökat med 45...
Patientrekryteringen till Active Biotechs kliniska fas II-studie för TASQ avslutad
June 08, 2009 02:30 ET
|
Active Biotech
Studien är en 2:1 randomiserad, placebokontrollerad, dubbel-blind fas II-studie av 1 mg/dag TASQ jämfört med placebo. Studien omfattar symptomfria patienter med metastaserad, hormonresistent,...
Active Biotech Completes Patient Enrollment to TASQ Clinical Phase II study
June 08, 2009 02:30 ET
|
Active Biotech
The study is a 2:1 randomized, placebo-controlled, double-blind Phase II study of 1 mg/day TASQ versus placebo. The study encompasses symptom-free patients with metastatic, hormone-resistant, prostate...
Opdatering omkring det kliniske udviklingsprogram med Lu AA21004 til
behandling af depression
June 08, 2009 02:30 ET
|
H. Lundbeck A/S
H. Lundbeck A/S (Lundbeck) og Takeda Pharmaceutical Company Limited
(Takeda) har i dag sammen offentliggjort hovedresultaterne fra de
første tre kliniske undersøgelser i fase III...